Search research articles
Contact Us
Filters
Showing results (1-10 of 71) with videos related to
Page
of 8
Sort By:
Blood Reviews
|
December 2, 2004
Splenic marginal zone lymphoma
David Oscier, Roger Owen, Stephen Johnson
BMJ Case Reports
|
January 7, 2019
Resistant type II cryoglobulinaemic vasculitis successfully treated with bortezomib in a patient with SLE
Katherine Dutton, Sinisa Savic, Roger Owen, et al.
International Journal of Chronic Obstructive Pulmonary Disease
|
October 18, 2011
Bronchodilator efficacy and safety of indacaterol 150 μg once daily in patients with COPD: an analysis of pooled data
Eugene R Bleecker, Thomas Siler, Roger Owen, et al.
Therapeutic Advances in Respiratory Disease
|
July 2, 2011
Profiling the bronchodilator effects of the novel ultra-long-acting β2-agonist indacaterol against established treatments in chronic obstructive pulmonary disease
Claus Vogelmeier, Helgo Magnussen, Craig LaForce, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
June 14, 2002
Variation in the manganese superoxide dismutase gene (SOD2) is not a major cause of radiotherapy complications in breast cancer patients
Helen Green, Gillian Ross, John Peacock, et al.
Respiratory Medicine
|
March 15, 2011
Profiling the effects of indacaterol on dyspnoea and health status in patients with COPD
Paul W Jones, Donald A Mahler, Rupert Gale, et al.
International Journal of Chronic Obstructive Pulmonary Disease
|
September 22, 2010
Onset of action of indacaterol in patients with COPD: comparison with salbutamol and salmeterol-fluticasone
Beatrix Balint, Henrik Watz, Carolynn Amos, et al.
British Journal of Haematology
|
February 1, 2011
Feasibility and efficacy of administration of bortezomib-containing regimens to patients over the age of 70 years
Christopher Parrish, Julian Cromack, Sylvia Feyler, et al.
Respiratory Medicine
|
March 4, 2011
Indacaterol once-daily provides superior efficacy to salmeterol twice-daily in COPD: a 12-week study
Stephanie Korn, Edward Kerwin, Sibel Atis, et al.
The Journal of Asthma : Official Journal of the Association for the Care of Asthma
|
December 17, 2008
Efficacy and safety of indacaterol, a new 24-hour beta2-agonist, in patients with asthma: a dose-ranging study
Frank Kanniess, Louis-Philippe Boulet, Wladyslaw Pierzchala, et al.
Page
of 8
Search research articles
Search
Showing results (1-10 of 71) with videos related to
Sort By:
Page
of 8
Blood Reviews
|
December 2, 2004
Splenic marginal zone lymphoma
David Oscier, Roger Owen, Stephen Johnson
BMJ Case Reports
|
January 7, 2019
Resistant type II cryoglobulinaemic vasculitis successfully treated with bortezomib in a patient with SLE
Katherine Dutton, Sinisa Savic, Roger Owen, et al.
International Journal of Chronic Obstructive Pulmonary Disease
|
October 18, 2011
Bronchodilator efficacy and safety of indacaterol 150 μg once daily in patients with COPD: an analysis of pooled data
Eugene R Bleecker, Thomas Siler, Roger Owen, et al.
Therapeutic Advances in Respiratory Disease
|
July 2, 2011
Profiling the bronchodilator effects of the novel ultra-long-acting β2-agonist indacaterol against established treatments in chronic obstructive pulmonary disease
Claus Vogelmeier, Helgo Magnussen, Craig LaForce, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
June 14, 2002
Variation in the manganese superoxide dismutase gene (SOD2) is not a major cause of radiotherapy complications in breast cancer patients
Helen Green, Gillian Ross, John Peacock, et al.
Respiratory Medicine
|
March 15, 2011
Profiling the effects of indacaterol on dyspnoea and health status in patients with COPD
Paul W Jones, Donald A Mahler, Rupert Gale, et al.
International Journal of Chronic Obstructive Pulmonary Disease
|
September 22, 2010
Onset of action of indacaterol in patients with COPD: comparison with salbutamol and salmeterol-fluticasone
Beatrix Balint, Henrik Watz, Carolynn Amos, et al.
British Journal of Haematology
|
February 1, 2011
Feasibility and efficacy of administration of bortezomib-containing regimens to patients over the age of 70 years
Christopher Parrish, Julian Cromack, Sylvia Feyler, et al.
Respiratory Medicine
|
March 4, 2011
Indacaterol once-daily provides superior efficacy to salmeterol twice-daily in COPD: a 12-week study
Stephanie Korn, Edward Kerwin, Sibel Atis, et al.
The Journal of Asthma : Official Journal of the Association for the Care of Asthma
|
December 17, 2008
Efficacy and safety of indacaterol, a new 24-hour beta2-agonist, in patients with asthma: a dose-ranging study
Frank Kanniess, Louis-Philippe Boulet, Wladyslaw Pierzchala, et al.
Page
of 8